Journal
CLINICAL INFECTIOUS DISEASES
Volume 52, Issue 1, Pages 99-114Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciq067
Keywords
-
Categories
Funding
- National Health and Medical Research Council, Australia
- Austin Hospital Medical Research Foundation
- Royal Australasian College of Physicians
Ask authors/readers for more resources
There is significant diversity in methicillin-resistant Staphylococcus aureus (MRSA) clones arising in the community worldwide, with considerable geographical differences in typical antimicrobial resistance profiles. Many community clones of MRSA have a non-multidrug resistant antimicrobial profile, providing increased options for empirical and directed therapy of infections caused by these strains. However, the recent description of increasing non-beta lactam resistance in community clones of MRSA, especially USA300, provides a timely warning for clinicians making decisions about therapy for patients potentially infected with these strains. Continued monitoring of global epidemiology and emerging drug resistance data is critical for the effective management of these infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available